![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://recalls-rappels.canada.ca/en/alert-recall/heparin-sodium-5-dextrose-injection-out-specification
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-lactic-acid-citric-acid-and-potassium-bitartrate-85917.pdf
https://www.prnewswire.com/news-releases/large-commercial-payer-adds-phexxi-to-formulary-for-standard-plans-nationwide-301626008.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212789
http://www.pharmafile.com/news/635113/evofem-s-phase-iii-trial-reveals-fewer-utis-women-using-phexxi
https://www.prnewswire.com/news-releases/evofem-biosciences-announces-record-net-sales-and-phexxi-prescriptions-in-q4-2021-301463762.html
https://www.prnewswire.com/news-releases/house-rules-delivers-strong-initial-results-and-drives-phexxi-growth-301404476.html
https://www.prnewswire.com/news-releases/evofem-biosciences-announces-us-commercial-launch-of-phexxi-lactic-acid-citric-acid-and-potassium-bitartrate-the-first-and-only-non-hormonal-on-demand-prescription-contraceptive-vaginal-gel-301124288.html
https://www.prnewswire.com/news-releases/evofem-biosciences-announces-us-commercial-launch-of-phexxi-lactic-acid-citric-acid-and-potassium-bitartrate-the-first-and-only-non-hormonal-on-demand-prescription-contraceptive-vaginal-gel-301124288.html
https://www.prnewswire.com/news-releases/us-fda-approves-evofem-biosciences-phexxi-lactic-acid-citric-acid-and-potassium-bitartrate-the-first-and-only-non-hormonal-prescription-gel-for-the-prevention-of-pregnancy-301064469.html
https://www.prnewswire.com/news-releases/evofem-biosciences-reports-positive-top-line-results-from-phase-2b-study-of-amphora-for-prevention-of-chlamydia-and-gonorrhea-in-women-300967140.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-clenpiq-209589-sodium-picosulfate-magnesium-oxide-and-anhydrous-citric-acid-oral-solution-10-mg-35-g-and-12-g-1554960365.pdf
https://www.prnewswire.com/news-releases/ferrings-clenpiq-sodium-picosulfate-magnesium-oxide-and-anhydrous-citric-acid-oral-solution-for-colonoscopy-prep-now-available-300596614.html
http://www.fiercepharma.com/marketing/fda-promo-police-slap-four-more-pharmas-year-end-enforcement-spree
http://www.pharma-excipients.ch/2016/05/26/effervescent-tablets-a-safe-and-practical-delivery-system-for-drug-administration/
http://www.pharma-excipients.ch/2016/04/07/formulation-of-venlafaxine-hcl-as-gastro-retentive-tablet-using-different-concentration-of-hpmc-and-its-evaluation/
http://www.pharma-excipients.ch/2016/03/23/the-influence-of-co-formers-on-the-dissolution-rates-of-co-amorphous-sulfamerazine-excipient-systems/
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/06/nce-exclusivity-challenges-are-hot-hot-hot-ferring-lets-loose-with-the-latest-lawsuit-challenging-de.html